#Israel #Jerusalem #ViVac Pharma #Keren Leshem #RNA-Lipid Nanoparticle

ViVac Pharma Elevates Keren Leshem as CEO

In a significant move within the biotechnology industry, ViVac Pharma Ltd. has announced the appointment of Keren Leshem as its Chief Executive Officer. This pioneering synthetic biology company specializes in RNA-Lipid Nanoparticle (LNP) immunotherapies, which are rapidly gaining recognition for their potential to revolutionize cancer treatments.

Keren Leshem is a seasoned leader with nearly three decades of experience in the life sciences sector. Her previous accolades include recognition as a Technology Pioneer by the World Economic Forum and listings in Forbes and Entrepreneur as one of the most influential leaders in the field. Her depth of knowledge and expertise will be crucial as ViVac aims to enhance its unique platform that re-engineers viruses to create safe and effective immunotherapies.

ViVac's cutting-edge technology is crafted around utilizing established viral mechanisms to launch immune responses against cancerous cells. By reprogramming RNA to act like a virus without replication, the company's platform promises a significant leap in cancer treatment, targeting solid tumors that conventional therapies often struggle to address.

Under Leshem's leadership, ViVac is set to expedite its preclinical oncology pipeline, which includes promising research programs addressing liver, ovarian, and various other solid tumors. These are cancers that represent critical unmet needs for patients, specifically those resistant to standard treatment options. Leshem emphasized, "ViVac's scientific approach signifies a paradigm shift in oncology — harnessing the capacity of synthetic RNA to simulate the strength of viral immunity while ensuring safety through modern nanotechnology."

The ViVac leadership team is comprised of distinguished experts in their respective fields. Dr. Lior Nissim, who heads the Biomedical Synthetic Biology Lab, has developed pioneering techniques in cancer cell targeting. Similarly, Prof. Chezy Barenholz, a long-time expert in liposome technology and nanomedicine, is co-inventor of Doxil®, the first FDA-approved liposomal nanodrug, and ranks among the top cited scientists globally. Alongside them, Dr. Ron Lahav serves as the Chief Technology Officer, specializing in RNA delivery systems.

Investors supporting ViVac include renowned figures in the life sciences, such as Dr. Jean de Gunzburg and Tuomas Tenkanen, who bring extensive experience in biotechnology innovation and global commercialization strategies. According to Prof. Barenholz, "Keren’s leadership and the unparalleled skills of our pioneering team position ViVac at the forefront of RNA and nanomedicine innovations."

The global cancer immunotherapy market is anticipated to surpass $125 billion by 2032, driven largely by advancements in RNA-based therapies. ViVac’s modular RNA-LNP platform is designed for scalability across multiple cancer types, thereby facilitating rapid expansion beyond its initial research targets.

Keren Leshem’s vision for ViVac is ambitious, as she remarked, "There will come a time when future generations will look back in disbelief that cancer was once a leading cause of death. Our efforts are driving towards a future where synthetic biology and innovative RNA delivery systems transform cancer into a manageable condition."

In conclusion, ViVac Pharma stands at a pivotal juncture in its evolution, with Keren Leshem leading the charge toward the next generation of RNA-based cancer immunotherapies. This leadership change signals a commitment to harnessing synthetic biology in the fight against cancer, potentially changing the way we understand and treat this disease. For further information about ViVac Pharma and its innovative projects, visit www.vivacpharma.com.